Canada To Invest In Mississauga-Based Eurofins CDMO Alphora Inc

Project will strengthen domestic production of antibody and other protein-based therapies

The Government of Canada continues to strive for innovative solutions and prioritize the revitalization of long-term domestic biomanufacturing capacity, positioning Canada at the forefront of antibody therapeutic development.

Today, Charles Sousa, Parliamentary Secretary to the Minister of Public Services and Procurement, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a contribution of $22.4M through the Strategic Innovation Fund (SIF) to support a $64.1M project by Eurofins CDMO Alphora Inc.

This investment will support the construction of a new biologics facility, increasing domestic production capacity for antibodies and protein-based therapeutics that will allow Canadians to better respond to future pandemics. The facility will also enable Eurofins CDMO Alphora Inc. to accelerate clinical testing and the speed at which novel therapeutics are brought to market.

With this contribution, Eurofins CDMO Alphora Inc. will create 120 jobs and 65 co-op positions as well as have the ability to produce materials for clinical trials and meet commercial requirements for a production capacity of up to 24.9 million vials annually.

Quick facts

• Canada’s Biomanufacturing and Life Sciences Strategy presents a long‑term vision to protect Canadians against future pandemics and other health emergencies and to grow an innovative, competitive domestic life sciences sector.
• Eurofins CDMO Alphora Inc., part of the global network of Eurofins laboratories, is a contract development manufacturing organization located in Mississauga, Ontario. The Ontario facility specializes in biopharmaceutical research and development related to clinical and commercial applications of monoclonal antibody and other protein-based biologic therapeutics.
• In October 2023, Eurofins CDMO Alphora Inc. received a $2.5M grant from the Government of Ontario through the Ontario Together Fund, which supports the province’s pandemic readiness and health care resiliency.
• Budget 2021 provided a total of $2.2B over seven years toward growing a vibrant domestic life sciences sector and securing pandemic preparedness. This budget funding provides foundational investments to help build Canada’s talent pipeline and research systems, as well as to foster the growth of Canadian life sciences firms.